SCIENTIFIC REPORTS

Received: 25 May 2016 Accepted: 18 October 2016 Published: 17 November 2016

OPEN Structured plant metabolomics for the simultaneous exploration of multiple factors

Nikolay Vasilev¹, Julien Boccard², Gerhard Lang³, Ulrike Grömping⁴, Rainer Fischer^{1,5}, Simon Goepfert³, Serge Rudaz² & Stefan Schillberg¹

Multiple factors act simultaneously on plants to establish complex interaction networks involving nutrients, elicitors and metabolites. Metabolomics offers a better understanding of complex biological systems, but evaluating the simultaneous impact of different parameters on metabolic pathways that have many components is a challenging task. We therefore developed a novel approach that combines experimental design, untargeted metabolic profiling based on multiple chromatography systems and ionization modes, and multiblock data analysis, facilitating the systematic analysis of metabolic changes in plants caused by different factors acting at the same time. Using this method, target geraniol compounds produced in transgenic tobacco cell cultures were grouped into clusters based on their response to different factors. We hypothesized that our novel approach may provide more robust data for process optimization in plant cell cultures producing any target secondary metabolite, based on the simultaneous exploration of multiple factors rather than varying one factor each time. The suitability of our approach was verified by confirming several previously reported examples of elicitormetabolite crosstalk. However, unravelling all factor-metabolite networks remains challenging because it requires the identification of all biochemically significant metabolites in the metabolomics dataset.

Secondary metabolites play an important role in the adaptation of plants to environmental stress¹. Plants react to exogenous factors such as nutrients, hormones and light through signalling pathways that induce downstream stress responses including the modulation of gene expression and the regulation of a broad range of biochemical processes, resulting in the remodelling of metabolism². Key signalling molecules include Ca^{2+} , nitrates, phosphates, 2,4-dichlorophenoxyacetic acid (2,4-D), naphthalene acetic acid (NAA), indole acetic acid (IAA), 6-benzylaminapurine (BAP), kinetin, abscisic acid (ABA), jasmonates, salicylic acid, gibberellic acid (GA₃), ethylene, polyamines, cyclic nucleotides (cAMP and cGMP) and diacylglycerol^{2–4}. The accumulation of metabolites in stressed plants may also have economic significance¹ because signalling components or elicitors can be used to trigger the production of secondary metabolites in whole plants or plant cell and tissue cultures⁵.

Design of experiments (DOE) approaches are used to study the influence of multiple factors simultaneously, allowing the influence of each factor to be determined regardless of other parameters while maintaining independence between the assessment of different effects. This contrasts with the classic one factor at a time' approach, which is laborious, time consuming and lacks the ability to provide a global picture of molecular events⁶. Factorial designs have recently flourished in plant biology, where they have been used to optimize cultivation parameters for cell and tissue cultures^{7,8} and to increase the yield of metabolites^{9,10} or recombinant proteins¹¹ by medium optimization. However, most of these applications of DOE featured a small number of response variables when describing the corresponding system or process. A much more comprehensive multivariate strategy is needed to identify multiple inducible biomarkers in the plant metabolome following the application of diverse elicitors, so the combination of DOE and metabolomics is an attractive approach for the systematic evaluation of changes in plant secondary metabolism¹².

¹Department of Plant Biotechnology, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen 52074, Germany. ²School of Pharmaceutical Sciences, University of Lausanne and University of Geneva, 1211, Switzerland. ³Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel 2000, Switzerland. ⁴Department II–Mathematics, Physics and Chemistry, Beuth University of Applied Sciences, Berlin 13353, Germany. ⁵Institute for Molecular Biotechnology, RWTH Aachen University, Aachen 52074, Germany. Correspondence and requests for materials should be addressed to N.V. (email: nikolay.vasilev@ime.fraunhofer.de)

Metabolomics generates large, multi-dimensional datasets using automated analytical procedures such as gas chromatography or high-pressure liquid chromatography coupled to mass spectrometry (GC-MS and HPLC-MS). It is therefore necessary to reduce the dimensionality of the data using multivariate statistical methods. The complexity of data mining is enhanced further when the data originate from several sources (e.g. complementary chromatography systems or ionization modes) and data fusion strategies are therefore required. An additional difficulty is encountered when multiple input factors are varied simultaneously, because different sources of variation are mixed. The importance of multiple simultaneous metabolic effects has been underestimated in the past and here we addressed this challenge by combining several orthogonal techniques: reversed-phase ultra-high-pressure liquid chromatography (RP-UHPLC) with positive and negative electrospray ionization (ESI) modes, and hydrophilic interaction liquid chromatography (HILIC), both coupled to time of flight mass spectrometry (TOF-MS) to achieve greater coverage of the metabolome.

Several strategies have been developed for the simultaneous analysis of multiple datasets. The proposed data modelling approach is an extension of the multiple kernel learning method to orthogonal partial least squares discriminant analysis (OPLS-DA), i.e. consensus OPLS-DA, which combines data blocks using the weighted sum of $X \cdot X^T$ product association matrices corresponding to their linear kernel¹³. The OPLS-DA framework is advantageous for data interpretation because relevant metabolic variations are associated with predictive components, whereas unrelated variation is summarized in so-called orthogonal components¹⁴. In consensus OPLD-DA, the block weighting is based on modified RV-coefficients so that the Y response orientates the consensus kernel towards improved predictability. Cross-validation is carried out to assess the optimal model size and avoids overfitting, using DQ² (an adaptation of the conventional Q² value) for discriminant analysis¹⁵.

To our knowledge, this is the first systematic investigation of metabolic remodelling in plants following simultaneous multi-factorial treatment. This novel combination of metabolomics and experimental design, associated with the simultaneous analysis of multiblock omics data, is a powerful approach that allows us to unravel the metabolic responses in transgenic tobacco cells at a global level when diverse input factors such as macronutrients, plant growth regulators and light are varied simultaneously. Furthermore, this high-throughput screening system can be used for process optimization with metabolically engineered cell lines. Herein we hypothesize that product optimization using the simultaneous exploration of multiple factors may achieve more accurate and reproducible results than the assessment of one factor at a time.

Results

UHPLC-OTOF-MS fingerprinting. The acquisition of high-quality metabolomics data is an essential aspect of metabolic profiling because it facilitates the identification step. The UHPLC-QTOF-MS gradient conditions we applied allowed us to monitor more than 3500 features in the m/z range 100–1200 based on RP-UHPLC (ESI⁺ and ESI⁻ ion detection modes) and HILIC (ESI⁺ ion detection mode). Pareto scaling was applied as data normalization. The multiblock data fusion strategy we used allows the integration of datasets originating from different ionization (ESI⁺/ESI⁻) and separation (RP/HILIC) modes, yielding 1500, 1366 and 1368 variables for the RP/ESI⁺, RP/ESI⁻ and HILIC/ESI⁺ blocks, respectively. Some of the signals were present in all blocks, whereas others were found in only one or two data blocks and thus provided complementary information¹³. The target metabolites in methanol extracts, obtained from tobacco suspensions expressing *Valeriana officinalis* geraniol synthase (*VoGES*) gene, were identified based on mass fragmentation and the comparison of characteristic m/z species with internal or publicly accessible natural product databases.

Consensus OPLS-DA data modelling and metabolite identification. A supervised data mining approach (consensus OPLS-DA) was applied to determine the distinct metabolic changes caused by the simultaneous modulation of diverse input factors, and leave-one-out cross-validation (LOOCV) was carried out to evaluate the appropriate number of orthogonal components based on the DQ² parameter. A series of 1000 permutation tests was performed for each model by randomizing the original Y class response in order to assess the statistical validity of the models¹³.

Significant models were obtained for most of the factors with a prediction accuracy (PA) of 87–100% and a statistical significance of p < 0.01. Lower prediction accuracy was observed for GA₃ (PA = 62.5%, p = 0.013) and ethephon (PA = 60.4%, p = 0.015), whereas KH₂PO₄ (PA = 57.3%, p = 0.225) and MgSO₄ (PA = 47.9%, p = 0.62) were found to be statistically non-significant (Table 1). Random permutations of the design matrix simulate data under the null hypothesis, i.e. no effect of the experimental factor under study. Because similar or higher prediction accuracies could be achieved from randomly permutated designs, we decided to omit KH₂PO₄ and MgSO₄ from subsequent experiments aiming to identify metabolites and to determine their biological importance.

Next we used S-plots to highlight relevant metabolites based on their contributions to the model, reflecting both their amplitude of variation and their reliability¹⁴. This visualization method helps to identify biochemically significant metabolites based on their position in the S-plots. The ideal biomarker has a high covariance magnitude and high correlation reliability. This low risk of spurious correlations corresponds to the upper right quadrant (area 1) or lower left quadrant (area 4) of each S-plot. The biomarkers located in area 1 are associated with metabolites that become more abundant when the factor strength is enhanced or less abundant when the factor strength is reduced, i.e. an upregulation effect (metabolic levels⁽⁺⁾/factor⁽⁺⁾ or metabolic levels⁽⁻⁾/factor⁽⁻⁾). Similarly, the biomarkers in area 4 are linked to metabolites that become less abundant when the factor strength is reduced or more abundant when the factor strength is reduced, i.e. a downregulation effect (metabolic levels⁽⁻⁾/factor⁽⁺⁾ or metabolic levels⁽⁻⁾/factor⁽⁻⁾). Because all three data blocks (RPLC NEG, RPLC POS and HILIC) are integrated in a single model for each factor, ions detected by each analytical protocol can be associated in a combined S-plot.

High-resolution QTOF-MS/MS profiling allowed 45 compounds represented by some of the most significant features with respect to the factors we investigated (i.e. they were located in areas 1 and 4 of the S-plots) to be

	Prediction accuracy	Estimated p-value
KNO3	86.5%	< 0.001
NH ₄ NO ₃	100.0%	< 0.001
CaCl ₂	76.0%	< 0.001
KH ₂ PO ₄	57.3%	0.225
MgSO ₄	47.9%	0.62
2,4-D	97.9%	< 0.001
IAA	90.6%	< 0.001
NAA	100.0%	< 0.001
IBA	99.0%	< 0.001
DHZ	100.0%	< 0.001
Kinetin	100.0%	< 0.001
BAP	100.0%	< 0.001
MeJa	99.0%	< 0.001
Salicylic acid	96.9%	< 0.001
GA ₃	62.5%	0.013
Ethephon	60.4%	0.015
Cyclanilide	97.9%	< 0.001
ABA	93.8%	< 0.001
Light	97.9%	< 0.001

 Table 1. Performance indices of the consensus OPLS-DA models evaluated for each of the screened factors. Prediction accuracy was evaluated by leave-one-out-cross-validation, whereas a series of 1000 permutation tests allowed an empirical p-value to be estimated.

.....

tentatively identified, at least to the level of the compound class (Table 2). However, the complete identification of all other relevant metabolites remains challenging and these preliminary results may serve as a starting point for the further targeted isolation and purification of the metabolites of interest.

Simultaneous treatments reveal nutrient–metabolite and elicitor–metabolite networks. Our primary goal was to identify metabolites that respond to each factor treatment when multiple factors are modulated simultaneously. Using this approach, we avoided the restriction of experimental results caused by the artificially narrow experimental conditions of the one factor at a time approach. In the following sections, bold numbers in parentheses represent the compounds from the list of identified metabolites (Table 2).

Nutrients. KNO₃ treatment (Fig. 1) increased the abundance of several ions representing glutamine (**8**) and scopolin (**9**), but also single ions representing a 2,4-D metabolite (**14**) (t_R = 8.85 min; *m/z* 559.2755) and hexosyl geranidiol (**5**) (t_R = 5.96 min; *m/z* 355.1749). In contrast, KNO₃ caused the extracellular loss of potassium ions, detected as K⁺ (KHCOO)_n adducts (**44**), and inhibited the formation of nicotine (**45**), hydroxysphingosine (**10**) and C16:3 monoacylglycerol (**29**). Single ions representing the following compounds were also less abundant following treatment with KNO₃: trihydroxy-C18:2 acids (**37**, **38**) (t_R = 11.36/11.18 min; *m/z* 327.2170/327.2171), a dihydrozeatin (DHZ) adduct (**22**) (t_R = 3.26 min; *m/z* 354.1794), a cyclanilide metabolite (**33**) (t_R = 9.26 min; *m/z* 620.0896) and BAP glycoside (**26**) (t_R = 4.08 min; *m/z* 388.1647).

 NH_4NO_3 treatment (Fig. S1) induced the synthesis of the monoterpenoid derivatives malonyl-hexosyl-geraniol (4), pentosyl-hexosyl-geraniol (2) and malonyl-hexosyl-geranidiol (7) as well as scopolin (9). Two single ion species representing BAP glycosides were also more abundant following treatment with NH_4NO_3 , i.e. BAP glucoside (26) ($t_R = 3.94$ min; m/z 388.1634) and BAP riboside (27) ($t_R = 6.59$ min; m/z 358.1532), as well as a salicylic acid glucoside (30) ($t_R = 3.31$ min; m/z 323.0759). In contrast, auxin metabolites representing NAA (18) and 2,4-D (14) as well as single ions representing conjugated dihydroxy-C18:2 fatty acid (43) and hexosyl-hexosyl-geraniol (6) were less abundant following treatment with NH_4NO_3 .

The formation of three metabolites was strongly induced by calcium treatment: hydroxysphingosine (10), scopolin (9) and hexosyl-hexosyl-geraniol (6). Adenosine (11) synthesis was also stimulated by calcium and was represented by a single ion ($t_R = 2.65 \text{ min}$; *m/z* 268.1082) (Fig. S2). Several metabolites became less abundant following calcium treatment, namely C16:3 monoacylglycerol (29), geraniol derivatives produced by the heterologous geraniol synthase (1, 2, 4 and 7), and a fatty acid with conjugated triene (40) ($t_R = 12.15 \text{ min}$; *m/z* 325.2013).

Auxins. Numerous metabolites were influenced by IAA (Fig. S3). We observed an increase in the abundance of indole-3-carboxylic acid glucoside (17) and K⁺ (44). The monoterpenoid derivatives pentosyl-hexosyl-geraniol (2) and malonyl-hexosyl-geraniol (4), a DHZ glycoside (21) ($t_R = 6.56 \text{ min}$; *m/z* 384.1906) and its adduct (22), C16:3 monoacylglycerol (29) and nicotine (45) ($t_R = 3.8096 \text{ min}$; *m/z* 163.1254) were also more abundant following treatment with IAA. The formation of other metabolites was inhibited, particularly adenosine (11), scopolin (9), BAP glucoside (26), and the geraniol derivatives pentosyl-hexosyl-geranidiol (1) ($t_R = 5.76 \text{ min}$; *m/z* 487.2159), hexosyl-geranidiol (5) and malonyl-hexosyl-geranidiol (6) ($t_R = 8.96 \text{ min}$; *m/z* 501.2312).

No.	Metabolite name	Characteristic <i>m/z</i>	t _R (min)	Detection mode
		463.2174	5.7656	RPNEG
1	pentosyl-hexosyl-geranidiol	487.2159	5,7593	RPPOS
-		503.1882	5.7588	RPPOS
		447.2226	9.5952	RPPOS
		471 2209	9 5930	RPPOS
2	pentosyl-hexosyl-geraniol	487 1962	9 5926	RPPOS
		919 4505	9.6056	RPNEG
		339 1804	10 3455	RPPOS
3	hexosyl-geraniol	355 1536	10.3461	RPPOS
		425 1792	11 2494	RPPOS
4	malonyl-hexosyl-geraniol	441 1559	11 2498	RPPOS
5	hevosyl-geranidiol	355 1749	5 9561	RPPOS
5	nexosyr-geranitator	477 2335	8 9770	PPNEC
6	hexosyl-hexosyl-geraniol	501 2312	8 9609	PPPOS
7	malonyl hevoryl geranidiol	441 1744	6.9855	PPPOS
,	matony1-nexosy1-geranition	120.0408	10.6222	
		1/7 0752	10.0332	HUIC
6	dutamina	203 1505	10.0113	HUIC
ō	giutamme	420 2179	10.6260	
		439.21/8	10.6269	HILIC
		282.2814	10.6283	DDMEC
		191.0343	3.5987	RPNEG
		193.0516	3.5994	RPPOS
		193.0535	2.9972	HILIC
9	scopolin	355.1048	3.5976	RPPOS
		355.1061	3.0112	HILIC
		377.0863	3.5995	RPPOS
		399.0922	3.5982	RPNEG
		731.1788	3.5973	RPPOS
		280.266	15.0331	RPPOS
		298.2763	15.0274	RPPOS
10 by		298.2784	5.9910	HILIC
	hydroxysphingosine	309.2069	15.0493	RPNEG
		316.2867	15.0264	RPPOS
		316.2884	5.9926	HILIC
		338.2696	15.0462	RPPOS
		382.2419	15.0422	RPPOS
		136.0569	2.5932	HILIC
11	adenosine	268.1082	2.6470	HILIC
		535.2012	2.6454	HILIC
		176.008	5.5960	RPNEG
12	scopoletin	178.0277	5.5921	RPPOS
	scopoletin	191.0344	5.5952	RPNEG
		193.0452	5.5936	RPPOS
		104.0255	5.5948	RPNEG
		120.021	5.5951	RPNEG
	scopoletin derivative	133.0287	5.5925	RPPOS
		137.0604	5.5922	RPPOS
		148.0156	5.5950	RPNEG
		165.0563	5.5930	RPPOS
13		215.0347	5.5938	RPPOS
		292.9786	5.5956	RPPOS
		300.0546	5.5893	RPPOS
		308.0433	5.5902	RPPOS
		316.0304	5.5889	RPPOS
		324.0529	5.5906	RPPOS
		383.0782	5.5973	RPPOS
Conti	nued			

No	Metabolite name	Characteristic m/z	t ₋ (min)	Detection	
110.	Metabolite name	405.0578	5 5928	RPNEG	
		405.06	5.6036	RPPOS	
		423 9898	5.5906	RPPOS	
		439.0089	5.5900	RPNEG	
		439.0133	5.5951	RPPOS	
		629.0385	5 5924	RPNEG	
		820.0741	5 5947	PPNEC	
		160 9559	8 8354	RPNEG	
		164 9515	8 8336	PPNEC	
		170.0464	8 8 7 8 3	PPPOS	
		174 9733	8.8281	RPPOS	
		185.0569	8 8349	RPNEG	
		347.0196	8 8379	RPNEG	
		349.0374	8 8 264	PPPOS	
14	metabolite of $2.4 D(1)$	351.0158	8 8342	RITOS PDNEC	
14		375.0145	8 8 2 7 8	PPPOS	
		415.0057	8 8304	RITOS PDNEC	
		550 2755	8 8471	RPNEC	
		582 2721	8 9217	RDDOC	
		717.0207	0.0317	RFF03	
		710.0200	0.0341	DDNEC	
		/ 19.0288	0.032/	RENEG	
		907.3045	8.8428	RPNEG	
		124.9799	11.6/18	RPNEG	
		163.9575	11.6759	RPNEG	
15	metabolite of 2,4-D (2)	164.951	11.6/55	RPNEG	
		402.9077	11.6770	RPNEG	
		404.9042	11.6725	RPNEG	
		460.9137	7 2007	KPNEG	
14	metabolite of 2,4-D (3)	170.0482	7.3887	HILIC	
16		1/4.9/55	7.3879	HILIC	
		349.0398	/.386/	HILIC	
		118.0649	4.6888	RPPOS	
17		262.0/14	4.6832	RPNEG	
17	indole-3-carboxylic acid glucoside	322.0927	4.6813	RPNEG	
		346.0923	4.6828	RPPOS	
		105.0175	4.6807	KPPOS	
		105.0175	5.84/5	HILIC	
		108.0443	5.8300	HILIC	
		109.0283	5.8394	HILIC	
		117.0192	5.8514	HILIC	
		127.0403	5.8528	DDMEC	
		141.0702	9.1835	RPNEG	
		141.0/25	5.8253	HILIC	
		145.0526	5.8169	HILIC	
		159.0322	5.8371	HILIC	
18	metabolite of NAA (1)	167.0494	9.1845	RPNEG	
		181.0659	9.1840	RPNEG	
		199.0765	9.1833	RPNEG	
		204.107	5.8286	HILIC	
		209.06	9.1827	RPNEG	
		227.0711	9.1826	RPNEG	
		230.0709	5.8179	HILIC	
		231.0554	5.8478	HILIC	
		248.0818	5.8441	HILIC	
		249.0667	5.8482	HILIC	
		266.0926	5.8349	HILIC	
Contir	Continued				

No.	Metabolite name	Characteristic <i>m/z</i>	t _R (min)	Detection mode
		271.0456	9.1705	RPPOS
		339.1097	9.1620	RPPOS
		413.1212	9.1701	RPPOS
		452.1573	5.8402	HILIC
		457.1119	9.1727	RPPOS
		457.1131	5.8504	HILIC
		473.0864	5.8473	HILIC
		473.0876	9.1693	RPPOS
		480.188	5.8748	HILIC
		794.2701	5.8362	HILIC
		815.3345	9.1788	RPNEG
		867.2371	9.1825	RPNEG
		886.2783	5.8310	HILIC
		889.2184	9.1827	RPNEG
		101.023	7.9271	RPNEG
		131.0338	7.9234	RPNEG
		132.0298	7.9449	RPNEG
		141.0704	7.9282	RPNEG
		141.0706	7.9397	RPPOS
		161.0452	2.1990	RPNEG
		185.0612	7.9236	RPNEG
		209.0611	7.9270	RPNEG
		221.0668	7.9282	RPNEG
10	m at a halita of NAA (2)	263.0772	7.9266	RPNEG
19	metabolite of NAA (2)	300.0866	7.9416	RPNEG
		324.0873	7.9409	RPPOS
		389.1215	7.9262	RPNEG
		551.1765	7.9259	RPNEG
		614.2078	7.9002	HILIC
		619.1631	7.9120	RPPOS
		623.1633	7.9484	RPNEG
		635.1373	7.9012	HILIC
		918.244	7.9416	RPNEG
		1191.3449	7.9262	RPNEG
	IBA glycoside	364.1395	6.4291	RPNEG
20		386.1211	6.4297	RPNEG
		388.1387	6.4199	RPPOS
	glycoside of DHZ	222.138	6.5705	HILIC
		382.1723	2.2985	RPNEG
21		384.1896	2.2933	RPPOS
		384.1906	6.1062	HILIC
		384.1906	6.5631	HILIC
		422.1449	6.5183	HILIC
		220.1198	3.2585	KPNEG
	DHZ adduct DHZ metabolite	222.1346	3.2604	RPPOS
22		354.1794	3.2625	RPPOS
		354.1807	2.3623	HILIC
		398.1679	3.2561	KPNEG
23		148.0651	3.7100	HILIC
		222.13//	3./152	DDNEC
24		214.0732	2.7567	RPNEG
		216.09	4.0422	KPPOS
	kinetin glucoside	216.0905	4.0422	DDNEC
		370.1232	2./3/1	RENEG
		370.1424	4.0210	KPPO5
	1	3/8.1442	4.0310	TILIC
Contin	ued			

NoOutcome numeOutcome numeOutcomeOutcome25kinetin riboside216.03%5.01%3RPPOS348.11405.01%3RPPOS244.02823.3360RPPOS244.02823.3360RPPOS388.15433.3373RPPOS26888.16413.3333RPPOS388.16474.0927HILC2620.0074.0927HILC2763.88.16474.0897HILC283.88.16473.9345RPPOS388.16473.9345RPPOS39.003.9366RPNEG611.24594.0379HILC775.3003.9366RPNEG224.00356.5916RPNEG225.0056.5889RPPOS356.13556.5914RPNEG226.0056.5889RPPOS356.13556.5914RPNEG356.13556.5914RPNEG356.13556.5914RPNEG356.13556.5914RPNEG356.13559.2430RPPOS3579.2430RPPOS358.1529.2430RPPOS356.13559.2430RPPOS3579.2530RPNEG358.1529.2430RPPOS3579.2430RPNEG358.1529.2430RPPOS359.1529.2430RPNEG35018.1523.3041RPNEG35018.1523.3041RPNEG35018.1523.3041RPNEG <th>No</th> <th>Metabolite name</th> <th>Characteristic m/7</th> <th>t₋(min)</th> <th>Detection</th>	No	Metabolite name	Characteristic m/7	t ₋ (min)	Detection
23 kinetin riboside 346.114 5.0372 RPNGS 346.1144 5.0207 RPNGS 244.0928 3.9360 RPNEG 224.0928 3.9360 RPNEG 226.1073 3.9362 RPNGS 386.1458 3.9333 RPNGS 386.1471 4.0897 HILC 40.11452 3.9378 RPNGS 386.1471 3.9378 RPNGS 386.1471 3.9378 RPNGS 386.148 3.9333 RPNGS 386.148 3.9335 6.5116 451.117 3.9345 RPNGS 386.1355 6.5141 RPNEG 386.1355 6.5141 RPNGS 386.148 3.33341 RPNGS 386.148 <th>110.</th> <th></th> <th>216.0891</th> <th>5.0179</th> <th>RPPOS</th>	110.		216.0891	5.0179	RPPOS
 Antin Housan (1997) Antisi (1997) An	25	kinatin ribosida	346 1149	5.0193	PPNEC
34.120 0.020 0.020 0.0200 0		kinetin ridoside	249 1226	5.0195	PPDOS
26 BAP glucoside 26 BAP glucoside 26 BAP glucoside 27 BAP riboside 26 BAP riboside 27 BAP riboside 26 BAP riboside 27 BAP riboside 28 BAP riboside 29 C163 monoacylglycerol 29 C163 monoacylglycerol 29 C163 monoacylglycerol 20 C163 monoacylglycerol 20 C163 monoacylglycerol 21 C163 monoacylglycerol 23 C163 monoacylglycerol 23 C163 monoacylglycerol 24 0035 30,304 RPNG 25 9,24340 RPPOS 26 C163 monoacylglycerol 27 BAP riboside 30 C163 monoacylglycerol 31 Salicylic acid, dihexoyl-glucoside 32 cycanilide metabolite (1) 33 elicylic acid, dihexoyl-glucoside 33 elicylic acid, dihexoyl-glucoside 33 elicylic acid, dihexoyl-glucoside 33 eycanilide metabolite (1) 34 Salicylic acid, dihexoyl-glucoside 33 eycanilide metabolite (1) 34 Salicylic acid, dihexoyl-glucoside 34 Salicylic acid, dihexoyl-glucoside 35 eycanilide metabolite (1) 35 eycanilide metabolite (2) 36 C163 monoacylglycerol 37 C17 C160 C170 C170 C170 C170 C170 C170 C170 C17			224.0028	2.0260	DDNEC
 Angelic acid glucoside BAP glucoside Second Science Second Science			224.0928	4.0027	LULIC
 26 BAP glucoside 26 BAP glucoside 26 BAP glucoside 27 BAP riboside 28 BAP riboside 29 C16-3 monaexylglycerol 212 C1085 228 BAP riboside 235 C185 236 C185 235 C185 230 C163 monaexylglycerol 230 C184 2			226.107	4.0927	PPPOS
 BAP glucoside BAP riboside BAP ribosid			220.1075	3.9362	RPPUS
A Partionide metabolite (1) 38. Partionide metabolite (2) 39. Partionide metabolite (1) 39. Partionide metabolite (2) 30. Partionide metabolite (2) 31. Partionide metabolite (2) 31. Partionide metabolite (2) 31. Partionide metabolite (2) 32. Partionide metabolite (2) 33. Partionide metabolite (2) 34. Partionide metabolite (2) 35. Partionide metabolite (2) 36. Partionide metabolite (2) 37. Partionide metabolite (2) 37. Partionide metabolite (2) 38. Partionide metabolite (2) 39. Partionide metabolite (2) 39. Partionide metabolite (2) 30. Partionide metabolite (2) 31. Partionide metabolite (2) 32. Partionide metabolite (2) 33. Partionide metabolite (3) 33. Partio			386.1458	3.936/	RPNEG
 AP glucoside BAP riboside Continued 			388.1634	3.9383	RPPOS
440.1452 3.333 4PPOS 454.1317 3.3336 4PPOS 454.1317 3.3336 8.4PPOS 773.318 4.0373 4.0373 HILC 773.318 4.0373 4.0373 HILC 773.318 4.0373 4.0373 HILC 773.318 4.0373 4.0373 HILC 773.318 4.0373 6.5816 RPNEG 224.0935 6.5891 HPOS 356.1355 6.5914 RPNEG 236.16.3 nonoacylglycerol 307 310 308 alicylic acid glucoside 101.0281 3.3047 RPPOS 237 3.307 RPPOS 230 103.307 RPPOS 231 3.3048 RPNEG 232 3.3048 RPNEG 233.048 RPNEG 232 3.3048 RPNEG 233.048 RPNEG 232.3048 RPNEG 233.044 RPNEG 233.044 RPNEG 233.044 RPNEG 232.3048 RPNEG 233.044 RPNEG 233.044 RPNEG 233.044 RPNEG 233.044 RPNEG 233.047 RPPOS 233.048 RPNEG 233.041 RPNEG 233.041 RPNEG 233.041 RPNEG 241.10281 3.3041 RPNEG 257.1377 3.3077 RPNEG 257.1371 3.3044 RPNEG 257.1371 3.3044 RPNEG 257.1371 3.3044 RPNEG 257.1371 3.3048 RPNEG 257.1371 3.3041 RPNEG 257.1371 3.3041 RPNEG 26.1310 27.10 177.0566 3.3041 RPNEG 33.101 3.3041 RPNEG 33.101 3.3041 RPNEG 33.101 3.3041 RPNEG 3.3041 RPN	26	BAP glucoside	388.1647	4.0897	HILIC
30 443.131 3.3934 RPNEG 631.2459 4.0379 HILIC 773.3008 3.39366 RPNEG 775.3158 4.0637 HILIC 224.0935 6.5914 RPNEG 236.1355 6.5893 RPPOS 358.1532 6.5893 RPPOS 402.1407 6.5909 RPNEG 358.1532 6.5893 RPPOS 402.1407 6.5909 RPNEG 28 BAP ribotide 335.225 9.2430 29 C16:3 monoacylglycerol 325.2318 7.0100 HILIC 137.0229 3.3048 RPPOS 27.1397 3.3072 RPPOS 27.1397 3.3044 RPNEG 137.0229 3.3048 RPNEG 230.0759 3.3041 RPNEG 230.0759 3.3041 RPNEG 301.0316 3.3049 RPNEG 31 saticylic acid, dihexosyl-glucoside 485.127 3.3043 RPNEG 323.075 R3005 9.3973 RPNOS 31 saticylic acid,			410.1452	3.9378	RPPOS
30 312459 4.0379 HILC 773.3008 3.9366 RPNEG 775.3158 4.0637 HILC 224.0935 6.5916 RPNEG 226.1085 6.5893 RPOS 356.1355 6.5914 RPNEG 226.1085 6.5893 RPOS 356.1355 6.5914 RPNEG 28 BAP riboside 438.1187 4.1593 RPPOS 29 C16:3 monoacylglycerol 235.2318 7.0100 HILC 29 C16:3 monoacylglycerol 325.2318 7.0100 HILC 300 Salicylic acid glucoside 137.0229 3.3048 RPNEG 317.0229 3.3044 RPNEG 227.1397 3.3079 RPOS 320.759 3.3041 RPNEG 227.1397 3.3041 RPNEG 310 salicylic acid glucoside 137.0229 3.3041 RPNEG 320.0759 3.3041 RPNEG 227.1397 3.3041 RPNEG 310 salicylic acid glucoside 137.0238 3.7150 RPNEG 311 <t< td=""><td></td><td></td><td>454.1317</td><td>3.9345</td><td>RPNEG</td></t<>			454.1317	3.9345	RPNEG
30 salicylic acid glucoside 30 cyclanilide metabolite (1) 31 cyclanilide metabolite (2) 32 cyclanilide metabolite (2) 33 alicylic acid, dihexosyl-glucoside 33 alic			631.2459	4.0379	HILIC
30 30 775.3158 4.0637 HILC 224,0935 6.5916 RPNEG 226,0085 6.5898 RPPOS 356.1355 6.5914 RPNEG 358.152 6.5893 RPPOS 402.1407 6.5909 RPNEG 28 BAP ribotide 598.1542 4.1559 RPPOS 29 C16:3 monoacylglycerol 325.2295 9.2430 RPPOS 30 3.007 RPPOS 30 3.048 RPNEG 30.072 RPNOS 30.013 3.3041 RPNEG 30.0316 3.3041 RPNEG 30.04 RPNEG 3.3041 RPNEG 31 saticylic acid, dihexosyl-glu			773.3008	3.9366	RPNEG
 APPEG 224,0935 6,5916 RPPKG 226,1085 6,5893 RPPOS 358,1532 6,5909 RPNEG 402,1407 6,5909 RPNEG 438,1187 4,1593 RPPOS 598,1542 4,1593 RPPOS 598,1542 4,1593 RPPOS 225,2318 7,0100 HILIC 121,0281 3,3077 RPPOS 137,0229 3,3048 RPPOS 137,0229 3,3048 RPPOS 299,0764 3,3077 RPPOS 299,0764 3,3071 RPPOS 299,0764 3,3072 RPPOS 299,0764 3,3041 RPPOS 299,0764 3,3041 RPPOS 299,0764 3,3049 RPNEG 30,01316 3,3041 RPPOS 299,0764 3,3041 RPPOS 299,0764 3,3041 RPPOS 299,0764 3,3041 RPPOS 299,0764 3,3041 RPNEG 637,1167 3,0304 RPNEG 637,1167 3,0304 RPNEG 637,1167 3,0304 RPNEG 637,1167 3,0304 RPNEG 137,0238 3,7150 RPNEG 137,0238 3,7150 RPNEG 137,0238 3,7150 RPNEG 139,095 9,3596 RPPOS 21,0977 9,3597 RPOS 22,0976 9,2740 RPNEG 159,973 9,2740 RPNEG 159,97			775.3158	4.0637	HILIC
27 BAP riboside 226.1085 6.5889 RPPOS 356.1355 6.5914 RPNEG 38.1532 6.5893 RPPOS 28 BAP ribotide 402.1407 6.5909 RPNEG 29 C16:3 monoacylglycerol 325.2295 9.2430 RPPOS 29 C16:3 monoacylglycerol 325.2318 7.0100 HILIC 30 Samonacylglycerol 33048 RPPOS 30 salicylic acid glucoside 137.0229 3.3048 RPPOS 30.01.0316 3.3041 RPPOS 299.0764 3.3034 RPNEG 30.01.0316 3.3049 RPNEG 301.0316 3.3041 RPNEG 31 salicylic acid glucoside 137.0229 3.3044 RPNEG 637.1167 3.3054 RPNEG 303.0316 RPNEG 31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNOS 321.097 9.3597 RPPOS 321.097 9.3597 RPPOS 321.097			224.0935	6.5916	RPNEG
27 BAP riboside356.1352 358.15326.5914 6.5903RPNEG 30028 P0 <b< td=""><td></td><td></td><td>226.1085</td><td>6.5889</td><td>RPPOS</td></b<>			226.1085	6.5889	RPPOS
358.1532 6.5893 RPPOS 402.1407 6.5909 RPNEG 28 BAP ribotide 598.1542 4.1559 RPPOS 29 C16:3 monoacylglycerol 325.2295 9.2430 RPPOS 325.2318 7.0100 HILIC 3.077 RPPOS 325.2318 7.0100 HILIC 3.077 RPPOS 3307 3.079 3.3048 RPNEG 137.0229 3.3048 RPNEG 137.0229 3.048 RPNEG 29.0764 3.0341 RPPOS 301.0316 3.3041 RPNEG 301.0316 3.3041 RPNEG 621.1426 3.3023 RPNEG 633.0792 3.3044 RPNEG 633.0792 3.3044 RPNEG 31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 32 cyclanilide metabolite (1) 339.1095 9.3596 RPNEG 321.097 9.3597 RPPOS 93.596 RPNEG	27	BAP riboside	356.1355	6.5914	RPNEG
40402.14076.5909RPNEG28BAP ribotide438.11874.1593RPPOS29C16:3 monoacylglycerol325.22359.2430RPPOS325.22359.2430RPPOS325.22317.0100HILICN121.02813.3077RPPOS137.02293.3048RPPOS137.02293.3048RPPOS257.13973.3079RPPOS290.07643.3041RPPOS257.13973.3079RPPOS290.07643.3041RPPOS33.041RPPOS290.07643.3041RPPOS33.047RPPOS320290.07643.3041RPPOS3.041RPPOS3213.013163.3041RPPOS63.711673.3054RPNEG653.07923.3044RPNEG653.07923.3044RPNEG31alicylic acid, dihexosyl-glucoside137.02383.7150RPNEG931alicylic acid, dihexosyl-glucoside137.02383.7150RPNEG321.09779.3597RPDOS33.0497RPNEG932cyclanilide metabolite (1)33.910959.3596RPNEG933.19059.3596RPNEG159.7139.2749RPNEG934.19619.3783RPNEG159.9739.2749RPNEG934.19619.3784RPNEG159.9739.2749RPNEG934.19619.3783RPNEG159.9759.2764RPNEG135.0119.2740RPNEG159.9759.2758RPNEG <td></td> <td></td> <td>358.1532</td> <td>6.5893</td> <td>RPPOS</td>			358.1532	6.5893	RPPOS
28 BAP ribotide438.11874.1593RPPOS29 C16.3 monoacylglycerol325.22959.2430RPNCG325.22187.0100HILIC307RPPOS3088.1121.02813.3077RPPOS3098.1121.02813.3072RPPOS257.13973.3048RPNEG1137.02293.3048RPNEG1137.02293.3041RPPOS257.13973.3079RPPOS299.07643.3041RPNEG299.07643.3041RPNEG30013.3041RPNEG30113.3041RPNEG3023.07593.3067RPPOS30304RPNEG663.07923.3044RPNEG663.07923.3044RPNEG663.07923.3044RPNEG943.21153.3038RPNEG318.16ylic acid, dihexosyl-glucoside485.127432rpPOS321.0979.359732cyclanilide metabolite (1)1339.10959.359633RPNEG934.19619.378333RPNEG153.01919.274033RPNEG159.9739.274933RPNEG159.9739.274933RPNEG159.9739.274034RPNEG159.9739.274035RPNEG159.9739.274034RPNEG159.9739.274035RPNEG159.9759.258835RPNEG227.99769.2761 <td></td> <td></td> <td>402.1407</td> <td>6.5909</td> <td>RPNEG</td>			402.1407	6.5909	RPNEG
20Initiation598,15424,1559RPNEG29C16.3 monoacylglycerol325,22959,2430RPPOS325,23187,0100HILIC121,02813,3077RPPOS137,02293,3048RPNEG135,04483,3072RPPOS299,07643,3034RPNEG299,07643,3041RPPOS299,07643,3041RPPOS299,07643,3041RPPOS303,3047RPPOS299,07643,3044RPNEG301,03163,3041RPNEG6637,11673,3067RPPOS391,10313,3048RPNEG6637,11673,3034RPNEG6637,01673,3044RPNEG6633,07923,3044RPNEG137,02383,7150RPNEG31salicylic acid, dihexosyl-glucoside137,02383,715032eyclanilide metabolite (1)137,02383,7150RPNEG33139,10959,3597RPPOS334934,19619,3783RPNEG934,19619,3783RPNEG159,0739,2740RPNEG161,98969,2791RPNEG161,98969,2791RPNEG161,98969,2791RPNEG161,98769,2742RPNEG179,0569,2764RPNEG161,98969,2790RPNEG161,98969,2790RPNEG179,0569,2764RPNEG161,98979,2764RPNEG	28	BAP ribotide	438.1187	4.1593	RPPOS
29 C16:3 monoacylglycerol325:2295 325:2189.2430 PC100RPPOS HILIC325:2187.0100HILIC325:2187.0100HILIC121.02813.3077RPPOS137.02293.3048RPPOS137.02293.3041RPPOS257.13973.3077RPPOS299.07643.3034RPNEG301.03163.3041RPPOS320.0593.3067RPPOS323.07593.3067RPNEG621.14263.3023RPNEG631.1673.30344RPNEG633.0723.3044RPNEG633.0723.3044RPNEG633.0723.3044RPNEG633.11673.3034RPNEG633.11673.3034RPNEG633.11673.3034RPNEG731salcylic acid, dihexosyl-glucoside137.0238332eyclanilide metabolite (1)333.093RPNEG333.0939.3596RPPOS333.0939.3596RPPOS334.1949.740RPNEG159.9739.2740RPNEG159.9739.2740RPNEG161.98969.2591RPNEG179.0569.2781RPNEG161.98969.2591RPNEG179.0569.2761RPNEG121.9449.2760RPNEG125.99559.2588RPNEG125.99559.2588RPNEG125.99559.2588RPNEG125.99559.2588RPNEG	20	Diff fiboliae	598.1542	4.1559	RPNEG
23 Chos initial oxygy et di 3252318 7.0100 HILIC 30 121.0281 3.3077 RPPOS 33048 RPNEG 137.0229 3.3048 RPNEG 30 257.1397 3.3079 RPPOS 30.016 3.3041 RPPOS 323.0759 3.3041 RPPOS 330.0346 RPNEG 621.1426 3.3023 RPNEG 621.1426 3.3044 RPNEG 621.1426 3.3044 RPNEG 637.1167 3.3044 RPNEG 317.0238 3.7150 RPNEG 318 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 321 cyclanilide metabolite (1) 339.1095 9.3597 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3597 RPOS <td>20</td> <td>C16.2 monocouldwarral</td> <td>325.2295</td> <td>9.2430</td> <td>RPPOS</td>	20	C16.2 monocouldwarral	325.2295	9.2430	RPPOS
30 31 32 33.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.307 3.303 3.304	29	C10:5 monoacyigiyceror	325.2318	7.0100	HILIC
 30 salicylic acid glucoside 3048 3072 3048 3072 3079 3010316 3044 3010316 3049 313993 32749 3040 304			121.0281	3.3077	RPPOS
30 salicylic acid glucoside 30 salicylic acid glucoside 185.0448 3.3072 RPPOS 2299.0764 3.3034 RPNEG 301.0316 3.3041 RPPOS 323.0759 3.3067 RPPOS 323.0759 3.3067 RPPOS 621.1426 3.3023 RPNEG 637.1167 3.3044 RPNEG 653.0792 3.3044 RPNEG 653.072 3.3044 RPNEG 637.1167 3.3038 RPNEG 637.1167 3.3038 RPNEG 635.0792 3.3044 RPNEG 635.0792 3.3044 RPNEG 637.1167 3.3038 RPNEG 137.0238 3.7170 RPNOS 32 cyclanilide metabolite (1) 137.0238 3.7172 RPPOS 331 cyclanilide metabolite (1) 339.1095 9.3596 RPPOS 332 cyclanilide metabolite (1) 339.1095 9.2740 RPNEG 341.961 9.3783 RPNEG 159.973 9.2740 RPNEG 341.961 9.3783 RPNEG			137.0229	3.3048	RPNEG
30 salicylic acid glucoside 30 salicylic acid glucoside 257.1397 3.3079 RPPOS 301.0316 3.3041 RPPOS 323.0759 3.3067 RPPOS 323.0759 3.3041 RPPOS 621.1426 3.3023 RPNEG 637.1167 3.3044 RPNEG 653.0792 3.3044 RPNEG 943.2115 3.3038 RPNEG 310 salicylic acid, dihexosyl-glucoside 177.0566 9.3597 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3596 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3590 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3596 RPNEG 321.0997 9.3597 RPDS 321.0997 9.2740 RPNEG			185.0448	3.3072	RPPOS
30 3.304 RPNEG 30.0316 3.3041 RPOS 323.0759 3.3067 RPOS 323.0759 3.3049 RPNEG 621.1426 3.3023 RPNEG 637.1167 3.3054 RPNEG 653.0792 3.3044 RPNEG 653.0792 3.3044 RPNEG 943.2115 3.3038 RPNEG 31 saticylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 32 cyclanilide metabolite (1) 137.0238 3.7150 RPNEG 331 saticylic acid, dihexosyl-glucoside 177.0566 9.3597 RPPOS 32 cyclanilide metabolite (1) 339.1095 9.3596 RPPOS 331 saticylic acid, dihexosyl-glucoside 177.0566 9.2740 RPNEG 331 cyclanilide metabolite (1) 339.1095 9.3596 RPPOS 332 cyclanilide metabolite (2) 153.0191 9.2740 RPNEG 34 lf9.973 9.2749 RPNEG			257.1397	3.3079	RPPOS
30 301.0316 3.041 RPPOS 323.0759 3.3067 RPPOS 599.1603 3.049 RPNEG 621.1426 3.023 RPNEG 637.1167 3.3044 RPNEG 637.1167 3.3044 RPNEG 633.0792 3.3044 RPNEG 943.2115 3.3038 RPNEG 31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 32 cyclanilide metabolite (1) 137.0238 3.7172 RPPOS 321.0997 9.3597 RPPOS 321.0997 9.3597 RPPOS 339.1095 9.3596 RPPOS 339.1095 9.3596 RPPOS 339.1095 9.3596 RPPOS 153.0191 9.2740 RPNEG 161.9896 9.2591 RPNEG 161.9896 9.2742 RPNEG 161.9896 9.2742 RPNEG 179.056 9.2742 RPNEG 384 cclanilide metabolite (2) 121.9976 9.2741 RPNEG			299.0764	3.3034	RPNEG
30 salicylic acid glucoside 323.0759 3.3067 RPPOS 599.1603 3.3049 RPNEG 621.1426 3.3023 RPNEG 637.1167 3.3044 RPNEG 637.1167 3.3044 RPNEG 653.0792 3.3044 RPNEG 943.2115 3.3038 RPNEG 31 alicylic acid, dihexosyl-glucoside 485.1274 3.7150 RPNEG 32 eyclanilide metabolite (1) 177.0566 9.3597 RPPOS 321.0997 9.3597 RPPOS 339.1095 9.3596 RPPOS 332.095 9.3596 RPPOS 153.0191 9.2740 RPNEG 934.1961 9.3783 RPNEG 161.9896 9.2591 RPNEG 161.9896 9.2591 RPNEG 161.9896 9.2742 RPNEG 179.056 9.2728 RPNEG 179.056 9.2750 RPNEG 161.9896 9.2751 RPNEG 187.9678 9.2742 RPNEG 121.0404 </td <td></td> <td></td> <td>301.0316</td> <td>3.3041</td> <td>RPPOS</td>			301.0316	3.3041	RPPOS
33 eyclanilide metabolite (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)	30	salicylic acid glucoside	323.0759	3.3067	RPPOS
33 eventset (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)			599.1603	3.3049	RPNEG
3.3054 RPNEG 637.1167 3.3054 RPNEG 653.0792 3.3044 RPNEG 943.2115 3.3038 RPNEG 31 alicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 32 eyclanilide metabolite (1) 137.0238 3.7150 RPPOS 32.0 eyclanilide metabolite (1) 177.0566 9.3597 RPPOS 339.1095 9.3596 RPPOS 339.1095 9.3596 RPPOS 934.1961 9.3783 RPNEG 934.1961 9.3783 RPNEG 934.1961 9.3783 RPNEG 159.973 9.2740 RPNEG 161.9896 9.2591 RPNEG 179.056 9.2728 RPNEG 131.0404 9.2750 RPNEG 121.0404 9.2750 RPNEG 121.0404 9.2750 RPNEG 121.0404 9.2750 RPNEG 121.0404 9.2750 RPNEG 121.9976<			621.1426	3.3023	RPNEG
653.0792 3.3044 RPNEG 943.2115 3.038 RPNEG 31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 32 eyclanilide metabolite (1) 177.0566 9.3597 RPPOS 32.10997 9.3596 RPPOS 934.1961 9.3783 RPNEG 958.1897 9.3600 RPPOS 153.0191 9.2740 RPNEG 159.973 9.2749 RPNEG 161.9896 9.2591 RPNEG 161.9896 9.2591 RPNEG 187.9678 9.2742 RPNEG 161.9896 9.2751 RPNEG 187.9678 9.2742 RPNEG 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 187.9678 9.2741 RPNEG 213.0404 9.2755 RPNEG 187.9678 9.2741 RPNEG 271.9874 9.2761 RPNEG 187.9678 9.2750 RPNEG 271.9874 9.2750 RPNEG 131.9993 9.2750 <td></td> <td></td> <td>637.1167</td> <td>3.3054</td> <td>RPNEG</td>			637.1167	3.3054	RPNEG
31 943.2115 3.3038 RPNEG 31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 32 eyclanilide metabolite (1) 177.0566 9.3597 RPPOS 339.1095 9.3596 RPPOS 934.1961 9.3783 RPNEG 958.1897 9.3600 RPPOS 153.0191 9.2740 RPNEG 161.9896 9.2591 RPPOS 179.056 9.2728 RPNEG 33.0191 9.2740 RPNEG 161.9896 9.2742 RPNEG 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 34 161.9896 9.2755 RPNEG 227.9976 9.2761 RPNEG 350 cyclanilide metabolite (2) 255.9955 9.2588 RPPOS 333.0993 9.2750 RPNEG 271.9874 9.2760 RPNEG 313.9993 9.2750 RPNEG 275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 275.9838 <			653.0792	3.3044	RPNEG
31 salicylic acid, dihexosyl-glucoside 137.0238 3.7150 RPNEG 485.1274 3.7172 RPPOS 32 cyclanilide metabolite (1) 177.0566 9.3597 RPPOS 321.0997 9.3596 RPPOS 339.1095 9.3596 RPPOS 33.1095 9.3596 RPPOS 934.1961 9.3783 RPNEG 958.1897 9.3600 RPPOS 153.0191 9.2740 RPNEG 159.973 9.2749 RPNEG 161.9896 9.2591 RPNEG 179.056 9.2728 RPNEG 179.056 9.2742 RPNEG 133.0404 9.2755 RPNEG 227.9976 9.2740 RPNEG 131.0404 9.2750 RPNEG 213.0404 9.2750 RPNEG 271.9874 9.2740 RPNEG 271.9874 9.2740 RPNEG 275.9838 9.2750 RPNEG 275.9838 9.2750 RPNEG 313.9993 9.2750 RPNEG 313.9993 9.2750 RPNEG<			943.2115	3.3038	RPNEG
31 salicylic acid, dihexosyl-glucoside 485.1274 3.7172 RPPOS 32 vcclanilide metabolite (1) 177.0566 9.3597 RPPOS 32.0 cyclanilide metabolite (1) 339.1095 9.3596 RPPOS 339.1095 9.3596 RPPOS 934.1961 9.3783 RPNEG 958.1897 9.3600 RPPOS 153.0191 9.2740 RPNEG 161.9896 9.2591 RPPOS 179.056 9.2728 RPNEG 33.0 cyclanilide metabolite (2) 179.056 9.2728 RPNEG 34.1961 9.2750 RPNEG 179.056 9.2742 RPNEG 35.0 179.056 9.2751 RPNEG 179.056 9.2751 RPNEG 35.9955 9.2588 RPNEG 121.0404 9.2750 RPNEG 213.0404 9.2750 RPNEG 271.9874 9.2761 RPNEG 213.0404 9.2750 RPNEG 275.9935 9.2588 RPPOS 271.9874 9.2750 R			137.0238	3.7150	RPNEG
32 introduction	31	salicylic acid, dihexosyl-glucoside	485.1274	3.7172	RPPOS
 32 cyclanilide metabolite (1) 321.0997 339.1095 339.1095 339.1095 9.3596 RPPOS 934.1961 9.3783 RPNEG 958.1897 9.3600 RPPOS 153.0191 9.2740 RPNEG 161.9896 9.2591 RPNEG 161.9896 9.2728 RPNEG 161.9876 9.2742 RPNEG 179.056 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2750 RPNEG 313.9993 9.2750 RPNEG 313.9993 9.2750 RPNEG 313.9993 9.2750 RPNEG 313.9993 9.2750 RPNEG 357.0818 9.2749 RPNEG 			177.0566	9.3597	RPPOS
32 cyclanilide metabolite (1) 111111 11111 111111 111111 111111 111111 111111 111111 111111 111111 111111 111111 1111111 11111111 1111111 <td rowspan="4">32</td> <td rowspan="5">cyclanilide metabolite (1)</td> <td>321.0997</td> <td>9.3597</td> <td>RPPOS</td>	32	cyclanilide metabolite (1)	321.0997	9.3597	RPPOS
33 cyclamic number of point (c) control (c) non-order (c) non-order (c) 33 cyclamilide metabolite (2) (2) <t< td=""><td>339.1095</td><td>9.3596</td><td>RPPOS</td></t<>			339.1095	9.3596	RPPOS
33 cyclanilide metabolite (2) 153.012 161.020 RFNEG 33 cyclanilide metabolite (2) 153.0191 9.2740 RPNEG 159.973 9.2749 RPNEG 161.9896 9.2591 RPPOS 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 187.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 313.9993 9.2750 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			934.1961	9.3783	RPNEG
33 153.107 150.007 11100 53.107 9.2010 RPNEG 153.0191 9.2740 RPNEG 159.973 9.2749 RPNEG 161.9896 9.2591 RPPOS 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 255.9955 9.2588 RPOS 263.0773 9.2750 RPNEG 275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			958 1897	9,3600	RPPOS
33 cyclanilide metabolite (2) 115,217,13 9,2749 RPNEG 159,973 9,2749 RPNEG 161,9896 9,2591 RPNEG 179,056 9,2728 RPNEG 187,9678 9,2742 RPNEG 213,0404 9,2755 RPNEG 227,9976 9,2761 RPNEG 255,9955 9,2588 RPOS 263,0773 9,2750 RPNEG 275,9838 9,2750 RPNEG 313,9993 9,2750 RPNEG 347.0969 9,2584 RPPOS 357.0818 9,2749 RPNEG			153.0191	9.2740	RPNEG
33 1333 32749 RFNEG 33 cyclanilide metabolite (2) 161.9896 9.2591 RPPOS 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2746 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			159 973	9 27/19	RPNFC
33 rol.3390 9.2391 RPPOS 179.056 9.2728 RPNEG 187.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 225.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2746 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			161 0806	9 2501	R PPDOC
33 i 179.056 9.27.28 RPNEG i 187.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 225.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2746 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG		cyclanilide metabolite (2)	101.9890	9.2591	DDNEC
33 I87.9678 9.2742 RPNEG 213.0404 9.2755 RPNEG 227.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2766 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			1/9.056	9.2728	RPNEG
33 213.0404 9.2755 RPNEG 237.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2753 RPNEG 213.0409 9.2750 RPNEG 271.9874 9.2750 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			18/.96/8	9.2/42	RPNEG
33 cyclanilide metabolite (2) 227.9976 9.2761 RPNEG 255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2761 RPNEG 271.9874 9.2750 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			213.0404	9.2755	RPNEG
255.9955 9.2588 RPPOS 263.0773 9.2750 RPNEG 271.9874 9.2746 RPNEG 275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG	33		227.9976	9.2761	RPNEG
263.0773 9.2750 RPNEG 271.9874 9.2746 RPNEG 275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			255.9955	9.2588	RPPOS
271.9874 9.2746 RPNEG 275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			263.0773	9.2750	RPNEG
275.9838 9.2753 RPNEG 313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			271.9874	9.2746	RPNEG
313.9993 9.2750 RPNEG 347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			275.9838	9.2753	RPNEG
347.0969 9.2584 RPPOS 357.0818 9.2749 RPNEG			313.9993	9.2750	RPNEG
357.0818 9.2749 RPNEG			347.0969	9.2584	RPPOS
Continued			357.0818	9.2749	RPNEG
	Conti	nued			

No.	Metabolite name	Characteristic <i>m/z</i>	t _R (min)	Detection mode
		476.0503	9.2743	RPNEG
		498.0332	9.2736	RPNEG
		527.2492	9.4612	RPNEG
		596.0928	9.2734	RPNEG
		618.0751	9.2752	RPNEG
		620.0896	9.2595	RPPOS
		159.9712	14.1734	RPNEG
34	cyclanilide metabolite (3)	566.9654	14.1686	RPNEG
		568.9623	14.1689	RPNEG
		153.0915	6.2662	RPNEG
35	ABA glycoside	425.1808	6.2678	RPNEG
		449.1792	6.2491	RPPOS
		139.076	4.4449	RPNEG
26	A D A match alita	279.1236	4.4451	RPNEG
30	ABA metabolite	303.1176	4.4479	RPNEG
		465.1742	4.4411	RPPOS
37	trihydroxy-C18:2 acid (1)	327.217	11.3581	RPNEG
38	trihydroxy-C18:2 acid (2)	327.2171	11.1797	RPNEG
39	glycoside of abscisic acid metabolite	281.1393	3.1053	RPNEG
		467.1902	3.0957	RPPOS
40	unidentified fatty acid with conjugatedtriene (1)	325.2013	12.1543	RPNEG
41	unidentified fatty acid with conjugated triene (2)	325.2012	10.1746	RPNEG
42	unidentified fatty acid with conjugated triene (3)	325.2011	9.9604	RPNEG
43	dihydroxy-C18:2 fatty acid (conjugated)	311.222	13.3326	RPNEG
44	potassium ion	122.9253	8.4619	HILIC
		206.8899	8.4611	HILIC
		290.8524	8.4597	HILIC
		458.7723	8.4606	HILIC
		542.7322	8.4597	HILIC
		878.5772	8.4627	HILIC
		106.0650	3.7917	HILIC
45	nicotine	120.0816	3.8033	HILIC
		163.1254	3.8096	HILIC

Table 2. List of identified metabolites.

Indole-3-butyric acid (IBA) treatment (Fig. S4) induced the synthesis of IBA glycoside (20), geraniol glycosides (2, 4) and C16:3 monoacylglycerol (29) but caused the loss of other metabolites including geraniol derivatives (1, 5, 6).

NAA treatment (Fig. S5) mainly increased the abundance of its own derivatives (**18**, **19**). The following metabolites became less abundant: several single ions characteristic of fatty acids with conjugated triene (**40–42**), trihydroxy-C18:2 acid (**37**), indole-3-carboxylic acid glucoside (**17**) ($t_R = 4.68 \text{ min}$; *m/z* 346.0923), pentosyl-hexosyl-geraniol (**2**), malonyl-hexosyl-geraniol (**4**) and nicotine (**45**).

The formation of several compounds was induced by 2,4-D treatment (Fig. S6): 2,4-D metabolites (14–16), adenosine (11) and the geraniol derivatives (1, 5, 6). Pentosyl-hexosyl-geraniol (2), malonyl-hexosyl-geraniol (4) and C16:3 monoacylglycerol (29) became less abundant.

Our observations show that naturally occurring (endogenous) auxins such as IAA and IBA upregulate (2 and 4) and downregulate (1, 5 and 6) the synthesis of geraniol glycosides, whereas the synthetic auxins (NAA and 2,4-D) have exactly the opposite effects on these metabolites.

Cytokinins. The presence of kinetin (Fig. S7) strongly induced the synthesis of kinetin glucoside (24) and kinetin riboside (25), and to a lesser extent the geraniol derivatives pentosyl-hexosyl-geraniol (2), malonyl-hexosyl-geraniol (4) and malonyl-hexosyl-geranidiol (7) as well as trihydroxy-C18:2 acid (37). DHZ treatment (Fig. S8) induced the formation of three derivatives: DHZ glycoside (21), DHZ adduct (22) and DHZ metabolite (23). BAP treatment (Fig. S9) resulted in the appearance of three derivatives: BAP glucoside (26), BAP riboside (27) and BAP ribotide (28).

Other plant growth regulators. Methyljasmonate (MeJa) treatment (Fig. S10) only induced the formation of C16:3 monoacylglycerol (**29**) to a significant extent, but we also observed smaller increases in the abundance





of a cyclanilide metabolite (**33**), hydroxysphingosine (**10**), nicotine (**45**), unidentified fatty acids with conjugated triene (**41**, **42**), trihydroxy-C18:2 acids (**37**, **38**), adenosine (**11**) and a 2,4-D metabolite (**14**). The only heterologous monoterpenoids induced by MeJa were pentosyl-hexosyl-geraniol (**2**) and malonyl-hexosyl-geranidiol (**7**). The formation of scopolin (**9**) was strongly inhibited, whereas the synthesis of hexosyl-hexosyl-geraniol (**6**), BAP riboside (**27**) and abscisic acid glycoside (**35**) was more weakly downregulated.

Salicylic acid treatment (Fig. S11) mainly induced the formation of its polar derivatives salicylic acid glucoside (**30**) and salicylic acid dihexosyl-glucoside (**31**), but also C16:3 monoacylglycerol (**29**), trihydroxy-C18:2 acid (**38**) and the unidentified fatty acids with conjugated triene (**41–43**). The monoterpenoids pentosyl-hexosyl-geraniol (**2**) and malonyl-hexosyl-geraniol (**4**) were also more abundant. Salicylic acid treatment inhibited the formation of a cyclanilide metabolite (**32**), a 2,4-D metabolite (**14**), scopoletin (**12**), a scopoletin derivative (**13**), hexosyl-hexosyl-geraniol (**6**) and BAP riboside (**27**).

GA₃ treatment (Fig. S12) induced the formation of C16:3 monoacylglycerol (**29**), pentosyl-hexosyl-geranidiol (**1**), trihydroxy-C18:2 acid (**37**), BAP glucoside (**26**), adenosine (**11**), malonyl-hexosyl-geranidiol (**7**), hexosyl-geranidiol (**5**), NAA metabolites (**18**, **19**) and the unidentified fatty acid with conjugated triene (**42**). It inhibited the formation of scopolin (**9**), a 2,4-D metabolite (**14**), hexosyl-geraniol (**3**), hexosyl-hexosyl-geraniol (**6**), a DHZ adduct (**22**) and a cyclanilide metabolite (**32**).

Ethephon treatment (Fig. S13) induced the formation of C16:3 monoacylglycerol (**29**), pentosyl-hexosylgeraniol (**2**), BAP glucoside (**26**), trihydroxy-C18:2 acid (**38**), scopolin (**9**) and malonyl-hexosyl-geraniol (**4**), but inhibited the formation of a DHZ adduct (**22**), adenosine (**11**), hydroxysphingosine (**10**), hexosyl-geranidiol (**5**), hexosyl-hexosyl-geraniol (**6**) and a cyclanilide metabolite (**32**).

Cyclanilide treatment (Fig. S14) induced the formation of its own metabolites (32–34) as well as one NAA metabolite (18), hexosyl-hexosyl-geraniol (6), unidentified fatty acids with conjugated triene (40–42), and trihydroxy-C18:2 acids (37, 38). The formation of numerous compounds was downregulated, including pentosyl-hexosyl-geraniol (2), malonyl-hexosyl-geraniol (4), C16:3 monoacylglycerol (29), pentosyl-hexosyl-geranidiol (1), conjugated dihydroxy-C18:2 fatty acid (43), scopolin (9), scopoletin (12) and malonyl-hexosyl-geranidiol (7).

ABA treatment (Fig. S15) resulted in the accumulation of ABA glycoside (**35**), an ABA metabolite (**36**) and its glycoside (**39**), trihydroxy-C18:2 acids (**37**, **38**), and to a lesser degree the unidentified fatty acids with conjugated triene (**40–42**), pentosyl-hexosyl-geranidiol (**1**) and malonyl-hexosyl-geranidiol (**7**). The abundance of DHZ (**22**), a 2,4-D metabolite (**14**), a cyclanilide metabolite (**32**), kinetin riboside (**25**), scopolin (**9**), and DHZ glycoside (**21**) declined in response to ABA.

Light. Light was the only physical factor we included in our experimental design, and it was associated with an increase in the levels of adenosine (11), two unidentified fatty acids with conjugated triene (41, 42), trihydroxy-C18:2 acids (37, 38), malonyl-hexosyl-geranidiol (7), and to a lesser extent glutamine (8), a 2,4-D metabolite (14) and C16:3 monoacylglycerol (29). Light inhibited the production of alkaloids, i.e. scopoletin (12), a scopoletin derivative (13) and scopolin (9), and the monoterpenoids pentosyl-hexosyl-geraniol (2), hexosyl-geraniol (3), and malonyl-hexosyl-geraniol (4). A DHZ adduct (22) and hydroxysphingosine (10) were also less abundant under strong illumination (Fig. S16).





Clustering. Cluster analysis provided a global overview of regulation events that follow changes in the experimental factors. This approach allows the grouping of metabolites with similar ion features using a dendrogram, and a heat map summarizes the contribution of each of the factors in the context of each identified metabolite and thus enables the visualization of upregulation and downregulation in response to different treatments (Fig. 2).

Both geranidiol glycosides (1 and 5) are located in a small cluster, whereas the third geranidiol derivative (7), an esterified monoglycoside, is found in a neighbouring cluster (Fig. 2). The geraniol metabolites (1 and 5) are upregulated by 2,4-D, DHZ, GA₃ and ABA and downregulated by NH₄NO₃, CaCl₂, IAA, IBA, BAP, salicylic acid and ethephon, whereas the upregulation of compound (7) is related to NH₄NO₃, kinetin, MeJa, GA₃, ABA, and light, and its downregulation is associated with CaCl₂, NAA, BAP and cyclanilide. The geraniol glycosides (2, 3 and 4) are located in a common larger cluster. These three metabolites are upregulated by IAA, IBA, kinetin and ethephon, but downregulated by CaCl₂, 2,4-D, NAA and light. Compounds (2 and 4) are distinguished from hexosyl-geraniol (3) mainly by the action of NH₄NO₃, i.e. (2 and 4) are upregulated whereas (3) is downregulated by NH₄NO₃. The heat map also shows the upregulation of hexosyl-hexosyl-geraniol (6) by CaCl₂, 2,4-D, BAP and cyclanilide, and its downregulation by NH₄NO₃, IAA, IBA, DHZ, MeJa, salicylic acid, GA₃, ethephon and ABA.

Discussion

The combination of fractional factorial design and consensus OPLS-DA methods allowed us to systematically explore the effect of multiple factors on plant metabolism, using transgenic tobacco cell cultures as a model system. This simultaneous application of treatment stress assesses all experimental factors under diverse conditions that could occur in nature. We tentatively identified 45 constituents in areas 1 and 4 of the S-plots following the fractionation and analysis of plant cell extracts by UHPLC-QTOF-MS, corresponding to metabolites whose abundance changed substantially in response to the experimental factors. These metabolites represented multiple classes of natural products: monoterpenoids, nitrogen-containing compounds, coumarins, fatty acids and their esters, and derivatives of phytohormones and plant growth regulators used as additives in the experiments.

Geraniol and its glycosides do not occur naturally in tobacco plants and their presence in our samples reflects the activity of the stably integrated *VoGES* gene¹⁶. However, the glycosylation profile of geraniol produced by our cell suspension cultures differed to that observed in whole plants. The cells produced seven distinct geraniol glycosides whereas 19 variants were produced by transgenic tobacco plants and *Nicotiana benthamiana* leaves used for transient expression. The acetylated glycosides produced at later stages of plant development were not monitored in our plant cell cultures. The cell suspension cultures produced geraniol glycosides, whereas the whole plants also produced geraniol glycosides with three or more sugar adducts. However, our cell suspension cultures accumulated geranidiol derivatives that are not produced in agroinfiltrated or transgenic plants, which instead produce geranic acid glycosides¹⁶.

Nitrogenous compounds are found in tobacco cells because they have multiple core metabolic functions and are also precursors in the biosynthesis of tobacco alkaloids¹⁷. Phytoalexins defend plants against biotic and abiotic stress¹⁸. The coumarin scopoletin (**12**) is one of the phytoalexins produced in tobacco^{19–21}. C16:3 monoacylg-lycerol (**29**) is a glyceride which can be formed by the esterification of glycerol with one fatty acid or by enzymatic hydrolysis of a fatty acid from diacylglycerol by the action of diacylglycerol lipase. Diacylglycerol acts as a

signalling molecule during plant development and in response to stress tolerance, nutrient deficiency and other environmental stimuli²²⁻²⁴.

Our metabolomic analysis showed that plant cells react strongly to phytohormones and plant growth regulators. Plants limit the impact of harmful xenobiotic compounds by hydroxylation, glutathione conjugation, glycosylation, malonylation and sulfonylation^{25,26}. Most of the phytohormone and growth regulator derivatives we identified were polar glucosylated products, which are generally more soluble than the parent molecule thus facilitating elimination. We also detected malonylated geraniol glycosides, confirming that malonylation is one of the key mechanisms used by tobacco cells to metabolize xenobiotic compounds²⁷.

The production of glutamine was strongly upregulated by KNO_3 treatment in our experiment. Nitrate is assimilated by plant cells from nitrite and ammonium, and is then converted into the amino acid glutamine²⁸. The protein kinase CIPK23 is involved in both nitrate and potassium signalling²⁹. CIPK23 phosphorylates nitrate transporter NPF6.3 after interacting with the calcineurin-B-like protein CBL9, and reduces nitrate uptake capacity in the presence of high external NO_3^- concentrations, whereas the CBL1-CIPK23 and CBL9-CIPK23 complexes activate the K⁺ channel AKT1³⁰. A monoacylglycerol derivative (**29**) was also less abundant following KNO_3 treatment. This may be a hydrolysis product of diacylglycerol which activates protein kinase C and induces nitrate reductase gene expression³¹.

The NO_3^-/NH_4^+ ratio in the culture medium influences the activity of auxins and cytokinins³². We observed an increase in the abundance of ions representing 2,4-D and the loss of ions representing DHZ metabolites and BAP glycoside in the KNO₃ S-plot, but an increase in the abundance of BAP glycosides and the loss of ions representing 2,4-D and NAA metabolites in the NH_4NO_3 S-plot. This indicates that the balance between NO_3^- and NH_4^+ ions may affect phytohormone sensitivity.

 NH_4NO_3 and $CaCl_2$ had the most significant impact on the biosynthesis of geraniol glycosides among the inorganic factors we tested. NH_4NO_3 induced the formation of geraniol glycosides (**2**, **4**, **7**) but inhibited the formation of hexosyl-hexosyl-geraniol (**6**), whereas calcium showed the opposite behaviour. Higher concentrations of useable nitrogen also enhanced the accumulation of linalool and citronellol by *Saccharomyces cerevisiae*³³. Geraniol blocks calcium and potassium channels in mammalian cells³⁴ and similar cyclic nucleotide-gated ion channels are found in plants³⁵.

 Ca^{2+} induced the hydroxylation of sphingosine and adenosine agreeing with previous observations that sphingosine-1-phosphate increases cytosolic free Ca^{2+36} and cyclic adenosine monophosphate regulates calcium channels in the plasma membrane of *Arabidopsis thaliana* leaf guard and mesophyll cells³⁷.

Scopolin and its 7-O-glucoside are key components of the abiotic stress response¹⁸ and the abundance of both compounds increased following treatment with all three statistically significant nutrients in our study. The accumulation of scopoletin in tobacco cells and its conversion to a glucoside is also induced by 2,4-D²¹. Ions representing scopolin were also detected following the treatment of our cells with 2,4-D. Scopoletin synthesis was strongly inhibited by MeJa concurring with data showing that scopoletin biosynthesis induced by *Alternaria alternata* is strongly dependent on jasmonic acid but not ABA, although MeJA does not induce scopoletin production in the absence of *A. alternata*³⁸. In our cells, the formation of scopoletin was also inhibited by GA₃.

We detected nicotine produced in trace amounts by our transgenic tobacco cell cultures, which comprise green (photosynthesizing) cells derived from the aerial parts of the plant, although *de novo* nicotine synthesis takes place mainly in the roots³⁹. MeJa induced nicotine production in our tobacco cells in a similar manner as previously shown for *N. attenuata*³⁹. The downregulation of nicotine production we observed following the treatment with KNO₃ and NAA agrees with previous reports for cultured tobacco callus, and the effect of K⁺ is probably mediated by NAA⁴⁰. We also observed that nicotine biosynthesis was induced by IAA but moderately suppressed by 2,4-D⁴¹. The combined effect of MeJa, auxins and K⁺ on the regulation of nicotine synthesis suggests that multiple factors contribute to the same process.

The biosynthesis of monoterpenoid glycosides appeared to be influenced by auxins and cytokinins, perhaps reflecting the antagonistic crosstalk between these two phytohormone classes⁴². Our experimental results support the idea that phytohormones function in a complex network involving the different hormonal pathways but that there is also elaborate crosstalk with nutrients and elicitors. The auxin-sensitive signalling protein SHY2 is regulated by the cytokinin-induced protein ARR1 (*Arabidopsis* response regulator), which in turn is repressed by gibberellin thus connecting three hormones in one network⁴². This may explain why our GA₃ S-plot contained ion traits that were also affected by auxins and cytokinins. We also observed evidence for ethylene/cytokinin and cytokinin/ABA crosstalk⁴².

Light has a potent effect on monoterpenoid metabolism by modulating the expression of monoterpenoid synthase genes, controlling precursor synthesis, and affecting constitutive promoter activity^{43,44}. Geraniol glycosides were also influenced by light in our cell cultures. Light induced the formation of malonyl-hexosyl-geranidiol (7) but suppressed the formation of pentosyl-hexosyl-geraniol (2), hexosyl-geraniol (3) and malonyl-hexosyl-geraniol (4).

We have developed a systematic approach, which implements an experimental design strategy in the context of metabolomics to account for the diverse factors applied simultaneously to plant cells. This is a valuable method for the investigation of complex environmental stress and its impact on plant metabolism by optimizing the number of experiments needed to assess the factors. Our approach significantly reduces the time and effort required for testing by using consensus OPLS-DA models to evaluate and interpret metabolic changes caused by the simultaneous application of diverse ecological factors. This systematic workflow may facilitate the discovery and characterization of factor-nutrient-elicitor networks and appropriate biomarkers. Finally, we conclude that this novel approach should be able to streamline process optimization for the reproducible production of any secondary metabolite in plant cell cultures by the simultaneous exploration of multiple factors rather than the assessment of one factor at a time.

Materials and Methods

Plant cell cultures, treatments and harvesting. We used tobacco (*N. tabacum* cv. Samsun NN) transgenic cell suspension cultures, expressing stably *V. officinalis* geraniol synthase. The cell cultures were initiated and maintained as previously described⁸. Two levels (low/high) were used for each of the factors selected for analysis. The low level of each macronutrient in the plant cell culture medium was based on classical Murashige and Skoog (MS) medium^{11,45} whereas the high level was based on our recent medium optimization study, although the concentrations of NH₄NO₃ were reversed^{11,45}. The specific low/high concentrations were prepared as follows: KNO₃ (18.79/70.16 mM), CaCl₂ (2.99/10.84 mM), KH₂PO₄ (1.25/2.72 mM), MgSO₄ (1.5/3.0 mM) and NH₄NO₃ (4.24/20.61 mM). For the auxins, cytokinins and plant regulators (IAA, IBA, NAA, 2,4-D, kinetin, DHZ, BAP, MeJa, salicylic acid, GA₃, ethephon, cyclanilide and ABA) the low and high levels were set to 0 and 10 μ M, respectively. Finally, the low and high levels of light were set to 11.50 and 35.62 μ mol/cm²/s, respectively⁸. The factor levels are summarized in Table S1.

The following cultivation conditions were used: flask volume 50 ml (Erlenmeyer glass flasks), filling volume 25 ml, inoculum size 1.4 g fresh weight (FW), triacetyl- β -cyclodextrin concentration 2 mM, and shaking frequency 180 rpm⁸. The plant cell suspension cultures were grown for 9 days before the cells were harvested, then filtered twice under vacuum and frozen at -20 °C. The cultures were elicited with phytohormones and plant growth regulators 6 days post-inoculation. The experiment was conducted at 26 °C with a 16-h photoperiod in an ISF1-X shaker (Kühner AG, Birsfelden, Switzerland).

Sample preparation. The samples were extracted as previously described⁴⁶. Briefly, ~100-mg aliquots of plant material were mixed with methanol (1:3 w/v) in a shaker mill (TissueLyser, Retsch, Haan, Germany) and pulverized with a steel ball at 25 beats per second for 1 min. Homogenized samples were sonicated (15 min), centrifuged (1750 × g, 10 min, 25 °C) and supernatants were passed through a 0.2- μ m membrane filter.

UHPLC-MS. The samples prepared above were analysed on an Acquity UPLC system coupled to a QTOF Premier MS detector (Waters, Milford, MA, USA). For RP-UHPLC, a Waters Acquity BEH C18 column $(2.1 \times 150 \text{ mm}, 1.7 \mu\text{m})$ was used with water containing 0.1% (v/v) formic acid (A) and acetonitrile containing 0.1% (v/v) formic acid (B) as eluents applied as the following gradient: 0 min, 5% B; 23.5 min, 80% B; 24 min, 96% B; 26 min, 96% B. The flow rate was 0.4 ml/min with the column temperature set to 45 °C. HILIC separation was carried out using a Waters Acquity HILIC column ($2.1 \times 150 \text{ mm}, 1.7 \mu\text{m}$) with 33 mM aqueous ammonium formate, pH 4.5 (A) and acetonitrile (B) as eluents applied as the following gradient: 0 min, 4% A; 3 min, 4% A; 17.5 min, 32% A; 18 min, 55% A; 20 min, 55% A. The flow rate was 0.5 ml/min with the column temperature set to 50 °C.

A pool was created by adding equal volumes from all samples to serve as a QC injection. Nine QC injections in total were distributed at regular intervals in the analytical batch. An acceptable variation was achieved for all peaks, including those with the highest intensity (coefficient of variation less than 40%).

Positive and negative ESI was applied in separate analytical runs (positive only for the HILIC method) with a desolvation gas flow of 780 l/h at 400 °C, a capillary voltage of 4.5 kV and a cone voltage of 45 V. Mass spectra were acquired over the m/z range 100–1200 in "W mode" using leucine enkephalin as a lock mass standard.

Raw data processing. Mass/retention time markers were extracted from the raw UHPLC-ESI-MS data using MarkerLynx XS v4.1 (Waters). The following method parameters were set: retention time window 1.6-24.6 min, m/z range 100-1200, XIC window 0.02 Da, peak smoothing activated, marker intensity threshold 30, mass window 0.04 Da, retention time window 0.2 min, noise elimination level 6.0, and deisotope data activated. All mass (m/z)/retention-time features related to the auxins, cytokinins and plant growth regulators provided as supplements in the plant cell culture media, as well as features derived from impurities in the LC eluents, were removed from the raw metabolomics datasets by removing all features detected in blank runs (solvent injection) or in analytical runs of the pure additives before data evaluation.

Experimental design. The experimental design was based on an orthogonal array with 96 runs created with the free open-source R package DoE.base⁴⁷ as described in the supplementary material. Given the size of this experiment, tests for effects of 2-level factors at significance level 5% can detect effects of size "one standard deviation" with about 99% power, effects of size "half a standard deviation" with about 68% power, and effects of size "0.75 standard deviations" with about 95% power. The design was optimized to screen 14 factors by keeping the confounding of low-order effects minimal: all main effects are orthogonal to each other (orthogonal array), the design was based on an array with the lowest possible number of squared canonical correlations from three-factor sets equal to 1⁴⁸ and the factors were accommodated on columns of the base array such that confounding between main effects and two-factor interactions, and subsequently among two-factor interactions, was minimized⁸.

This fractional factorial design, with a randomized run order, was used to screen 12 two-level factors, one three-level factor and one four-level factor: we thus screened for the effects of light and 18 diverse substances representing macronutrients, auxins, cytokinins and elicitors. For the two-level factors, we investigated the presence of the high levels of NH_4NO_3 , KNO_3 , $CaCl_2$, KH_2PO_4 , $MgSO_4$, MeJa, salicylic acid, GA_3 , ethephon, cyclanilide, ABA and light. For auxins (four-level factor), exactly one of IAA, IBA, NAA or 2,4-D was present, whereas for cytokinins (three-level factor), exactly one of kinetin, DHZ or BAP was present. The experimental design with 96 runs is summarized in coded values in Table S2. The remaining potentially relevant confounding between main effects and two-factor interactions in terms of triples of factor comparisons are summarized in Fig. S17. For each such triple, the comparison between the levels of each factor in the triple might be affected by an interaction between the other two factors (e.g. an interaction between KNO₃ and NH₄NO₃ might affect the assessment of the BAP vs. DH-z comparison for cytokinins). Sceptics might argue that this possibility for confounding is a reason

to refrain from using an experimental design approach in favour of only changing one factor at a time (OFAT approach). However, if two-factor interactions are indeed relevant – as would be necessary for the experimental design approach to suffer from misleading conclusions in terms of factor level comparisons – the conclusions from an OFAT approach are also limited in the same manner and would be valid only for the exact settings at which the other factors have been fixed. Furthermore, to achieve a reasonable amount of replication, the OFAT approach would need a much larger number of experimental runs – e.g. 24 runs for the reference level combination (the number obtained for the four-level factors (12*24), and 24 runs each for the other levels of the three-level and the four-level factors (5*24), resulting in a total of 18*24 = 432 runs instead of the 96 runs in our experiment.

Data processing and analysis. For each experimental factor, a consensus OPLS-DA model was built to relate the experimental metabolomics data (X) to a class matrix consisting of zeros and ones, filled according to the levels of each factor (Y). The columns of the experimental design were therefore used individually as a response matrix in the context of supervised analysis. For auxins and cytokinins, a response vector was generated individually for each hormone and filled with zero when the corresponding hormone was absent, whereas a value of one indicated its presence. The consensus OPLS algorithm implements data fusion based on multiple kernel learning. The joint analysis of multiple data tables is achieved by the combination of association matrices computed for each block. Therefore, requirements in terms of memory resources and computation time are minimized without information loss even if the experimental data include a large number of signals. A block-scaling step ensures fairness between blocks by offering equal starting chances to contribute to the model. RV coefficients are then computed to build a consensus matrix and orientate the model towards better prediction performance. A common subspace is built using a kernel version of the OPLS algorithm and the optimal number of orthogonal components is estimated by cross-validation. Because systematic variations are summarized using Y-predictive and Y-orthogonal components (OPLS framework), the interpretation of the multiblock model is straightforward. Like classical multivariate methods, a consensus score plot allows the distribution of the observations to be evaluated. Because linearity is maintained, variable loadings can easily be computed for biomarker discovery. The weight of each block in the projection also allows the role of each data source to be evaluated¹³. The OPLS model can be summarized as follows:

$$X(i) = t_{p}(j)p_{p}^{T}(i, j) + t_{o}(j)p_{o}^{T}(i, j) + E(i, j)$$
(1)

$$Y(j) = t_{p}(j)q_{p}^{T}(i, j) + F(i, j)$$
(2)

where X contains the normalized metabolomic data from data block i (i \in [RPPOS, RPNEG, HILICPOS]), Y represents a 0/1 indicator variable for experimental condition j (j \in [NH₄NO₃, KNO₃, CaCl₂, KH₂PO₄, MgSO₄, IAA, IBA, NAA, 2,4-D, kinetin, DHZ, BAP, MeJa, salicylic acid, GA₃, ethephon, cyclanilide, ABA, light]), t_p is the Y-predictive score matrix, p_p is the Y-predictive loading matrix for X, t_o is the Y-orthogonal score matrix, p_o is the Y-orthogonal loading matrix for X, q_p is the Y-predictive loading matrix for Y, and E and F are the residual matrices for X and Y, respectively. Note that the four indicator variables for the cytokinins sum to a column of "+1" entries, as do the three indicator variables for the auxins. Consensus OPLS-DA modelling was carried out under the MATLAB[®] v8 environment (The MathWorks, Natick, USA) with combinations of toolboxes and in-house functions, including the publicly available RV-coefficients MATLAB m-file⁴⁹ and the KOPLS open source package⁵⁰.

Cluster analysis. Subsets of metabolites sharing similar patterns were investigated using cluster analysis. For that purpose, the contribution (loading) of each ion feature associated with an identified metabolite was collected across all significant consensus OPLS-DA models and displayed in a dendrogram and a heat map. This strategy highlights upregulation and downregulation. Cluster analysis was carried out with the Bioinformatics Toolbox v4.2 under the MATLAB[®] v8 environment (The MathWorks) using Euclidean distances and the Ward aggregation method.

Factors with more than two levels. Auxins and cytokinins were two factors in our design associated with three and four levels, respectively. Exactly one auxin and one cytokinin were included in each run of the experimental design. Consequently, the four Y(j) indicator columns corresponding to auxins and the three Y(j) indicator columns corresponding to cytokinins are linearly dependent, as stated above. Our analysis included all indicator columns, because each is treated separately. This implies that downregulation or upregulation must be interpreted within the linearly-dependent groups, e.g. if the three auxins IAA, IBA and 2,4-D are identified as downregulators, the fourth (NAA) must be an upregulator (relative to the other auxins). This behaviour is clearly shown in the heat map and also implies analogous dependencies among the S-plots of the auxins and cytokinins, respectively.

References

- 1. Ramakrishna, A. & Ravishankar, G. A. Influence of abiotic stress signals on secondary metabolites in plants. *Plant Signal Behav* 6, 1720–1731 (2011).
- 2. Tuteja, N. & Sopory, S. K. Chemical signaling under abiotic stress environment in plants. *Plant Signal Behav* 3, 525–536 (2008).
- 3. Karuppusamy, S. A review on trends in production of secondary metabolites from higher plants by *in vitro* tissue, organ and cell cultures. *J Med Plants Res* 3, 1222–1239 (2009).
- 4. Ramachandra Rao, S. & Ravishankar, G. A. Plant cell cultures: Chemical factories of secondary metabolites. *Biotech Adv* 20, 101–153 (2002).

- 5. Zhao, J., Davis, L. C. & Verpoorte, R. Elicitor signal transduction leading to production of plant secondary metabolites. *Biotech Adv* 23, 283–333 (2005).
- Vaidya, B. K., Mutalik, S. R., Joshi, R. M., Nene, S. N. & Kulkarni, B. D. Enhanced production of amidase from *Rhodococcus* erythropolis MTCC 1526 by medium optimisation using a statistical experimental design. *J Ind Microbiol Biotechnol* 36, 671–678 (2009).
- 7. Nas, M. N., Eskridge, K. M. & Read, P. E. Experimental designs suitable for testing many factors with limited number of explants in tissue culture. *Plant Cell Tiss Organ Cult* **81**, 213–220 (2005).
- Vasilev, N., Schmitz, C., Grömping, U., Fischer, R. & Schillberg, S. Assessment of cultivation factors that affect biomass and geraniol production in transgenic tobacco cell suspension cultures. *PLoS One* 9, e104620 (2014).
- 9. Prakash, G. & Srivastava, A. K. Statistical elicitor optimization studies for the enhancement of azadirachtin production in bioreactor *Azadirachta indica* cell cultivation. *Biochem Eng J* **40**, 218–226 (2008).
- Srivastava, S. & Srivastava, A. K. Statistical medium optimization for enhanced azadirachtin production in hairy root culture of Azadirachta indica. In Vitro Cell Dev Biol. Plant 48, 73–84 (2012).
- 11. Vasilev, N. *et al.* Optimization of BY-2 cell suspension culture medium for the production of a human antibody using a combination of fractional factorial designs and the response surface method. *Plant Biotechnol J* **11**, 867–874 (2013).
- 12. Marti, G. *et al.* Metabolomics reveals herbivore-induced metabolites of resistance and susceptibility in maize leaves and roots. *Plant Cell Environ* **36**, 621–639 (2013).
- Boccard, J. & Rutledge, D. N. A consensus orthogonal partial least squares discriminant analysis (OPLS-DA) strategy for multiblock Omics data fusion. Anal Chim Acta 769, 30–39 (2013).
- Wiklund, S. et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 80, 115–122 (2008).
- 15. Westerhuis, J. A., van Velzen, E. J. J., Hoefsloot, H. C. J. & Smilde, A. K. Discriminant Q(2) (DQ(2)) for improved discrimination in PLSDA models. *Metabolomics* 4, 293–296 (2008).
- Dong, L. et al. Characterization of two geraniol synthases from Valeriana officinalis and Lippia dulcis: Similar activity but difference in subcellular localization. Metab Eng 20, 198–211 (2013).
- 17. Ghosh, B. Polyamines and plant alkaloids. Indian J Exp Biol 38, 1086-1091 (2000).
- Jeandet, P., Clement, C., Courot, E. & Cordelier, S. Modulation of phytoalexin biosynthesis in engineered plants for disease resistance. *Int J Mol Sci* 14, 14136–14170 (2013).
- Grosskinsky, D. K. et al. Cytokinins mediate resistance against Pseudomonas syringae in tobacco through increased antimicrobial phytoalexin synthesis independent of salicylic acid signaling. Plant Physiol 157, 815–830 (2011).
- Taguchi, G., Yazawa, T., Hayashida, N. & Okazaki, M. Molecular cloning and heterologous expression of novel glucosyltransferases from tobacco cultured cells that have broad substrate specificity and are induced by salicylic acid and auxin. *Eur J Biochem* 268, 4086–4094 (2001).
- 21. Taguchi, G., Yoshizawa, K., Kodaira, R., Hayashida, N. & Okazaki, M. Plant hormone regulation on scopoletin metabolism from culture medium into tobacco cells. *Plant Sci* 160, 905–911 (2001).
- 22. Dong, W., Lv, H., Xia, G. & Wang, M. Does diacylglycerol serve as a signaling molecule in plants? *Plant Signal Behav* 7, 472–475 (2012).
- Okazaki, Y. & Saito, K. Roles of lipids as signaling molecules and mitigators during stress response in plants. *Plant J* 79, 584–596 (2014).
- Singh, A., Bhatnagar, N., Pandey, A. & Pandey, G. K. Plant phospholipase C family: Regulation and functional role in lipid signaling. Cell Calcium 58, 139–146 (2015).
- Kreuz, K., Tommasini, R. & Martinoia, E. Old enzymes for a new job (herbicide detoxification in plants). *Plant Physiol* 111, 349–353 (1996).
- 26. Sandermann, H. Jr. Higher plant metabolism of xenobiotics: the 'green liver' concept. Pharmacogenetics 4, 225-241 (1994).
- 27. Taguchi, G. *et al.* Malonylation is a key reaction in the metabolism of xenobiotic phenolic glucosides in *Arabidopsis* and tobacco. *Plant J* **63**, 1031–1041 (2010).
- 28. Betti, M. *et al.* Glutamine synthetase in legumes: recent advances in enzyme structure and functional genomics. *Int J Mol Sci* 13, 7994–8024 (2012).
- 29. Tsay, Y. F., Ho, C. H., Chen, H. Y. & Lin, S. H. Integration of nitrogen and potassium signaling. Annu Rev Plant Biol 62, 207–226 (2011).
- 30. Leran, S. et al. Nitrate sensing and uptake in Arabidopsis are enhanced by ABI2, a phosphatase inactivated by the stress hormone abscisic acid. Sci Signal 8, ra43 (2015).
- Chandok, M. R. & Sopory, S. K. ZmcPKC70, a protein kinase C-type enzyme from maize. Biochemical characterization, regulation by phorbol 12-myristate 13-acetate and its possible involvement in nitrate reductase gene expression. *J Biol Chem* 273, 19235–19242 (1998).
- 32. George, E. F., Hall, M. A. & De Klerk, G.-J. *Plant propagation by tissue culture. The background* Vol. 1 (Springer, Dordrecht, The Netherlands, 2008).
- Carrau, F. M. et al. De novo synthesis of monoterpenes by Saccharomyces cerevisiae wine yeasts. FEMS Microbiol Lett 243, 107–115 (2005).
- 34. de Menezes-Filho, J. E. et al. Geraniol blocks calcium and potassium channels in the mammalian myocardium: useful effects to treat arrhythmias. Basic Clin Pharmacol Toxicol 115, 534–544 (2014).
- 35. Kaplan, B., Sherman, T. & Fromm, H. Cyclic nucleotide-gated channels in plants. FEBS Lett 581, 2237-2246 (2007).
- 36. Wu, J. et al. Long-chain base phosphates modulate pollen tube growth via channel-mediated influx of calcium. Plant J **79**, 507–516 (2014).
- Lemtiri-Chlieh, F. & Berkowitz, G. A. Cyclic adenosine monophosphate regulates calcium channels in the plasma membrane of Arabidopsis leaf guard and mesophyll cells. J Biol Chem 279, 35306–35312 (2004).
- 38. Sun, H. *et al.* Scopoletin is a phytoalexin against *Alternaria alternata* in wild tobacco dependent on jasmonate signalling. *J Exp Bot* **65**, 4305–4315 (2014).
- Baldwin, I. T. Methyl jasmonate-induced nicotine production in Nicotiana attenuata: Inducing defenses in the field without wounding. Entomol Exp Appl 80, 213–220 (1996).
- Piñol, M. T., Palazón, J., Altabella, T., Cusido, R. & Serrano, M. Effect of auxin on alkaloids, K⁺ and free amino acid content in cultured tobacco callus. *Physiol Plantarum* 65, 299–304 (1985).
- 41. Furuya, T., Kojima, H. & Syono, K. Regulation of nicotine biosynthesis by auxins in tobacco callus tissues. *Phytochemistry* **10**, 1529–1532 (1971).
- El-Showk, S., Ruonala, R. & Helariutta, Y. Crossing paths: cytokinin signalling and crosstalk. *Development* 140, 1373–1383 (2013).
 Lu, S. *et al.* Cloning and functional characterization of a beta-pinene synthase from *Artemisia annua* that shows a circadian pattern of expression. *Plant Physiol* 130, 477–486 (2002).
- Schnurr, J. A. & Guerra, D. J. The CaMV-35S promoter is sensitive to shortened photoperiod in transgenic tobacco. *Plant Cell Rep* 19, 279–282 (2000).
- Murashige, T. & Skoog, F. A revised medium for rapid growth and bio assays with tobacco tissue cultures. *Physiol Plantarum* 15, 473–497 (1962).

- De Vos, R. C. H. et al. Untargeted large-scale plant metabolomics using liquid chromatography coupled to mass spectrometry. Nat Protoc 2, 778–791 (2007).
- Grömping, U. DoE.base: Full factorials, orthogonal arrays and base utilities for DoE packages. Package version 0.27. Available: https://cran.r-project.org/web/packages/DoE.base/index.html. Accessed 18 Aug 2015.
- 48. Grömping, U. & Xu, H. Q. Generalized resolution for orthogonal arrays. Ann Statist 42, 918-939 (2014).
- Smilde, A. K., Kiers, H. A. L., Bijlsma, S., Rubingh, C. M. & van Erk, M. J. Matrix correlations for high-dimensional data: the modified RV-coefficient. *Bioinformatics* 25, 401–405 (2009).
- Bylesjö, M., Rantalainen, M., Nicholson, J. K., Holmes, E. & Trygg, J. K-OPLS package: kernel-based orthogonal projections to latent structures for prediction and interpretation in feature space. BMC Bioinformatics 9, 106 (2008).

Acknowledgements

This research was funded by the European Union Seventh Framework Programme SmartCell (Rational design of plant systems for sustainable generation of value-added industrial products, Grant agreement No. 222716). We acknowledge technical assistance by C. Schmitz and editorial assistance by R. M. Twyman.

Author Contributions

N.V. and S.S. conceived this project; N.V. and U.G. designed the experiments; N.V. and G.L. performed the experiments; J.B., N.V., U.G. and S.R. analysed data; N.V., J.B., U.G. and G.L. wrote the paper with input from S.S., S.G., S.R. and R.F. All the authors discussed the results and commented on the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Vasilev, N. *et al.* Structured plant metabolomics for the simultaneous exploration of multiple factors. *Sci. Rep.* **6**, 37390; doi: 10.1038/srep37390 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016